drugset
drugset / Trial / NCT00569036

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

NCT00569036 ↗

Phase 1 Completed 63 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies

Timeline

Start
2008-04
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-754807 Small molecule 4 mg Oral
Subject BMS-754807 Small molecule 10 mg Oral
Subject BMS-754807 Small molecule 20 mg Oral
Subject BMS-754807 Small molecule 30 mg Oral
Subject BMS-754807 Small molecule 50 mg Oral
Subject BMS-754807 Small molecule 70 mg Oral
Subject BMS-754807 Small molecule 100 mg Oral
Subject BMS-754807 Small molecule 130 mg Oral
Subject BMS-754807 Small molecule 160 mg Oral
Subject BMS-754807 Small molecule 200 mg Oral

Indications

metastatic neoplasm neoplasm